Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 20,110 Shares of Stock

Zymeworks Inc. (NYSE:ZYME) insider Paul Andrew Moore sold 20,110 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $504,761.00. Following the transaction, the insider owned 31,212 shares of the company’s stock, valued at approximately $783,421.20. The trade was a 39.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Zymeworks Price Performance

Shares of NYSE ZYME opened at $25.48 on Tuesday. The firm has a market capitalization of $1.91 billion, a PE ratio of -16.99 and a beta of 1.30. Zymeworks Inc. has a 1-year low of $9.03 and a 1-year high of $28.49. The business’s fifty day moving average price is $23.87 and its two-hundred day moving average price is $18.03.

Zymeworks (NYSE:ZYME) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business had revenue of $27.61 million during the quarter, compared to analyst estimates of $33.69 million. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. The company’s quarterly revenue was up 72.6% on a year-over-year basis. Equities research analysts expect that Zymeworks Inc. will post -1.39 earnings per share for the current fiscal year.

Institutional Trading of Zymeworks

Several institutional investors have recently modified their holdings of the company. EcoR1 Capital LLC grew its holdings in Zymeworks by 33.1% during the second quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock worth $288,278,000 after acquiring an additional 5,710,840 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Zymeworks by 184.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company’s stock valued at $46,210,000 after purchasing an additional 2,514,834 shares in the last quarter. Millennium Management LLC grew its stake in shares of Zymeworks by 851.6% in the 3rd quarter. Millennium Management LLC now owns 1,104,813 shares of the company’s stock worth $18,870,000 after purchasing an additional 988,711 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Zymeworks by 169.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,326,774 shares of the company’s stock worth $22,661,000 after purchasing an additional 833,994 shares in the last quarter. Finally, Vestal Point Capital LP lifted its stake in Zymeworks by 130.0% during the second quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $14,432,000 after purchasing an additional 650,000 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Stifel Nicolaus boosted their price objective on Zymeworks from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Citigroup started coverage on Zymeworks in a research note on Wednesday, December 3rd. They set an “outperform” rating on the stock. Citizens Jmp started coverage on Zymeworks in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $32.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of Zymeworks from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Finally, HC Wainwright increased their target price on shares of Zymeworks from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Eleven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Zymeworks currently has a consensus rating of “Buy” and an average price target of $32.82.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.

The company’s core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties.